Home › Funds › SEVEN GRAND MANAGERS, LLC › SYRE
SEVEN GRAND MANAGERS, LLC position in SYRE
SPYRE THERAPEUTICS INC · Health Care
SEVEN GRAND MANAGERS, LLC reported holding 225,000 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$20.0M, representing 0.80% of its reported portfolio and ranking #28 among its reported holdings. SEVEN GRAND MANAGERS, LLC has disclosed SYRE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How SEVEN GRAND MANAGERS, LLC's SYRE position evolved
SEVEN GRAND MANAGERS, LLC first disclosed a stake in SYRE in Q4 2025 at 100,000 shares (US$3.3M). The position peaked in Q2 2026 at 225,000 shares, worth US$20.0M. Across 3 filings, SEVEN GRAND MANAGERS, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 225,000 shares valued at US$20.0M — an increase of 125,000 shares quarter over quarter.. Notable position changes include a 125% increase in Q2 2026 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 100.00K | $3.28M | New |
| Q1 2026 | 100.00K | $5.04M | Hold |
| Q2 2026 | 225.00K | $19.98M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SYRE and 13F data
SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 70 other funds we track also report a position in SYRE — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$377.5M), Paradigm Biocapital Advisors LP (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SYRE
- PERCEPTIVE ADVISORS LLC 4.32M sh · $383.48M · Q2 2026
- RTW INVESTMENTS, LP 4.25M sh · $377.49M · Q2 2026
- Paradigm Biocapital Advisors LP 3.84M sh · $340.98M · Q2 2026
- Venrock Adviser, LLC 2.99M sh · $265.05M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.80M sh · $248.51M · Q2 2026
- TCG Crossover Management, LLC 1.90M sh · $168.73M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.89M sh · $167.99M · Q2 2026
- Remedium Capital Partners, LLC 1.46M sh · $129.99M · Q2 2026
- Affinity Asset Advisors, LLC 1.28M sh · $113.56M · Q2 2026
- Siren, L.L.C. 968.60K sh · $85.99M · Q2 2026
- BRAIDWELL LP 879.47K sh · $78.08M · Q2 2026
- Commodore Capital LP 846.79K sh · $75.18M · Q2 2026
More on SEVEN GRAND MANAGERS, LLC
FAQ
How long has SEVEN GRAND MANAGERS, LLC held SYRE?
SEVEN GRAND MANAGERS, LLC has disclosed SYRE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is SEVEN GRAND MANAGERS, LLC's current position in SYRE?
As of Q2 2026, SEVEN GRAND MANAGERS, LLC holds 225.00K shares of SYRE (SPYRE THERAPEUTICS INC), valued at $19.98M, representing 0.80% of its reported portfolio and ranking #28.
Has SEVEN GRAND MANAGERS, LLC been buying or selling SYRE?
In the latest 13F filing (Q2 2026), SEVEN GRAND MANAGERS, LLC increased its position in SYRE. The position peaked in Q2 2026 at 225.00K shares.
Which other funds hold SYRE?
Other major institutional holders of SYRE include PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.